PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
8.51%
Revenue growth exceeding 1.5x VET's 0.29%. David Dodd would verify if faster growth reflects superior business model.
15.86%
Cost increase while VET reduces costs. John Neff would investigate competitive disadvantage.
3.37%
Gross profit growth 50-75% of VET's 5.52%. Martin Whitman would scrutinize competitive position.
-4.74%
Margin decline while VET shows 5.22% expansion. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-10.83%
G&A reduction while VET shows 2.95% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
175.00%
Other expenses growth 1.25-1.5x VET's 119.35%. Martin Whitman would scrutinize cost items.
-11.33%
Operating expenses reduction while VET shows 3.95% growth. Joel Greenblatt would examine advantage.
2.95%
Total costs growth while VET reduces costs. John Neff would investigate differences.
-3.16%
Interest expense reduction while VET shows 4.55% growth. Joel Greenblatt would examine advantage.
13.17%
D&A growth while VET reduces D&A. John Neff would investigate differences.
21.09%
EBITDA growth 50-75% of VET's 41.07%. Martin Whitman would scrutinize operations.
23.82%
EBITDA margin growth while VET declines. John Neff would investigate advantages.
28.63%
Operating income growth exceeding 1.5x VET's 9.30%. David Dodd would verify competitive advantages.
18.54%
Operating margin growth exceeding 1.5x VET's 8.98%. David Dodd would verify competitive advantages.
-53.91%
Other expenses reduction while VET shows 89.99% growth. Joel Greenblatt would examine advantage.
8.84%
Pre-tax income growth below 50% of VET's 619.30%. Michael Burry would check for structural issues.
0.31%
Pre-tax margin growth below 50% of VET's 617.79%. Michael Burry would check for structural issues.
-97.61%
Tax expense reduction while VET shows 229.28% growth. Joel Greenblatt would examine advantage.
165.94%
Similar net income growth to VET's 190.79%. Walter Schloss would investigate industry trends.
160.77%
Similar net margin growth to VET's 189.94%. Walter Schloss would investigate industry trends.
167.80%
Similar EPS growth to VET's 181.69%. Walter Schloss would investigate industry trends.
167.80%
Similar diluted EPS growth to VET's 185.71%. Walter Schloss would investigate industry trends.
-0.12%
Share count reduction while VET shows 0.00% change. Joel Greenblatt would examine strategy.
-0.16%
Diluted share reduction while VET shows 0.00% change. Joel Greenblatt would examine strategy.